Key facts
- Notable investors include Auckland UniServices.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Amacas
- ·The full record, as it builds
Funding rounds
No funding rounds for Amacas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amacas
Developer of animal health pharmaceuticals intended to extend the health span of companion animals. The company offers a weight management pharmaceutical characterized by targeted formulation, controlled dosage, and veterinary applicability with a focus on addressing obesity-related conditions in pets, enabling veterinarians and pet owners to manage weight effectively while supporting longevity, improved quality of life, and overall health outcomes for companion animals.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2025
- Ownership
- Privately Held (backing)
Amacas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amacas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amacas in its N-PORT filings yet. We sweep new filings monthly.